Affordable Access

deepdyve-link
Publisher Website

Miller Fisher syndrome associated with COVID-19: an up-to-date systematic review

Authors
  • Li, Zheng1
  • Li, Xingye2
  • Shen, Jianxiong1
  • Chan, Matthew T.V.3
  • Wu, William Ka Kei3, 3
  • 1 Department of Orthopaedic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100042 China
  • 2 Department of Orthopedic Surgery, Beijing Jishuitan Hospital, Fourth Clinical College of Peking University, Jishuitan Orthopaedic College of Tsinghua University, Beijing, China
  • 3 The Chinese University of Hong Kong,
Type
Published Article
Journal
Environmental Science and Pollution Research
Publisher
Springer-Verlag
Publication Date
Mar 06, 2021
Pages
1–6
Identifiers
DOI: 10.1007/s11356-021-13233-w
PMID: 33677662
PMCID: PMC7936860
Source
PubMed Central
Keywords
License
Unknown

Abstract

Recently, during the pandemic infection of the novel SARS-CoV-2, some cases of Miller Fisher syndrome (MFS) have been reported. We want to summarize the main features of patients with MFS and COVID-19. A PubMed search was performed on 8 October to identify references reporting cases with MFS associated with COVID-19 from the first report of COVID-19 to 8 October 2020 using the following keywords: “Miller Fisher syndrome” AND “COVID-19” OR “SARS-CoV-2”. A systematic review from the first report of coronavirus disease 2019 (COVID-19) to 8 October 2020 revealed 7 cases with Miller Fisher syndrome (MFS) associated with COVID-19. The 7 cases came from 5 countries but most of these patients were from Europe (85.7%), especially Spain. There are 5 cases of MFS diagnosed after the laboratory confirmation of SARS-CoV-2 infection. The mean onset time of MFS-associated neurological symptoms was 14.75 days after the diagnosis of COVID-19. However, the two remaining cases presented initially with MFS-associated neurological symptoms followed by the diagnosis of COVID-19. The most common symptoms of COVID-19-associated MFS were perioral paresthesias (57.1%), ataxia (57.1%), blurred vision (42.9), ophthalmoplegia (42.9), and generalized areflexia (42.9). However, more cohort and case-control studies are required to establish the epidemiological linkage.

Report this publication

Statistics

Seen <100 times